Rappta Therapeutics has entered into a global licensing agreement with SpringWorks Therapeutics for RPT04402, a novel anti-cancer drug targeting PP2A, with a $13 million upfront payment and potential for significant milestone payments.

Target Information

Rappta Therapeutics, based in Finland, is a biotechnology company dedicated to developing innovative anti-cancer drugs that specifically activate protein phosphatase 2A (PP2A). The company has pioneered unique technologies leveraging high-resolution structural data, facilitating the creation of a novel class of anti-cancer therapies that target PP2A, an essential enzyme in regulating protein dephosphorylation related to tumor growth. Historical challenges in directly targeting PP2A make Rappta's advancements particularly significant.

Noteworthy among Rappta's pre-clinical developments is RPT04402, a first-in-class molecular glue specifically aimed at PP2A complexes. This drug has shown promising results in pre-clinical models, demonstrating rapid and sustained tumor regressions in cases of uterine cancer driven by PP2A mutations, targeting a high unmet clinical need.

Industry Overview

The cancer treatment industry in Finland, while growing, remains a challenging field, with a substantial emphasis on targeted therapies. The increasing prevalence of malignancies, coupled with an aging population, has compelled healthcare stakeholders to prioritize adva